A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Migraine in Children
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 12 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- H. Lundbeck A/S
- Last updated on ClinicalTrials.gov
- August 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Ki Health Partners LLC DBA New England Institute for Clinical Research · Stamford, CT
Florida · 3
- NW FL Clinical Research Group, LLC · Gulf Breeze, FL
- AGA Clinical Trials - Hialeah - 4980 W 10th Ave · Hialeah, FL
- University of South Florida - 13330 USF Laurel Dr · Tampa, FL
Kentucky · 1
- University of Kentucky HealthCare (UKHC) Kentucky Clinic · Lexington, KY
Ohio · 1
- Cincinnati Children's Hospital Medical Center - PIN · Cincinnati, OH
Texas · 1
- Road Runner Research Ltd · San Antonio, TX
Virginia · 1
- Children's Specialty Group (CSG) · Norfolk, VA
West Virginia · 1
- Marshall Health-Marshall University Medical Center · Huntington, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.